J&J agrees to resolve 42 US states' talc investigations
Johnson & Johnson has toay reported quarterly results just above Wall Street expectations, helped by strong sales of its blockbuster psoriasis drug Stelara, which is expected to face fresh US competition from biosimilar versions next year.
Business
• 23 Jan 24
